Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Beta Bionics, Inc. Director's Dealing 2025

Jan 31, 2025

32351_dirs_2025-01-31_2fd18845-0b01-4bff-b3b5-dfde7dfc49ff.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Beta Bionics, Inc. (BBNX)
CIK: 0001674632
Period of Report: 2025-01-29

Reporting Person: Russell Steven Jon (N/A)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2025-01-29 Employee Stock Option (right to buy) $17 A 90637 Acquired 2035-01-28 Class B Common Stock (90637) Direct

Footnotes

F1: Vesting is monthly over a 48-month period starting January 29, 2025 in equal monthly amounts.

F2: Immediately prior to the closing of the initial public offering, each share of Class B Common Stock subject to this option was converted into an equal number of shares of Common Stock.